Short Term Rating on Medivation (MDVN)

Medivation (MDVN) : 13 analysts are covering Medivation (MDVN) and their average rating on the stock is 1.62, which is read as a Buy. 9 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 5, which recommends a Strong Sell affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Medivation (MDVN) has been rated by 14 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $76 and the lowest price target forecast is $40. The average forecast of all the analysts is $62.57 and the expected standard deviation is $9.77.

For the current week, the company shares have a recommendation consensus of Buy.


Medivation (NASDAQ:MDVN): The stock opened at $62.59 on Tuesday but the bulls could not build on the opening and the stock topped out at $62.64 for the day. The stock traded down to $62.05 during the day, due to lack of any buying support eventually closed down at $62.15 with a loss of -0.13% for the day. The stock had closed at $62.23 on the previous day. The total traded volume was 1,687,993 shares.

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *